C2N, WUSTL Expand Partnership to Commercialize Alzheimer's Test | GenomeWeb

NEW YORK (GenomeWeb) – C2N Diagnostics today announced the expansion of a partnership with Washington University School of Medicine in St. Louis to commercialize a clinical blood test for the detection of Alzheimer's disease at its earliest stages, as well as mild cognitive impairment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.